[Risedronate, a new diphosphonate in osteoporosis and Paget's disease].
Bannwarth
B
B
Service de rhumatologie, Groupe hospitalier Pellegrin et Laboratoire de thérapeutique, EA 525, Université Victor Segalen, Bordeaux. bernard.bannwarth@u-bordeaux2.fr
D000368:Aged; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D003348:Cortisone / Q000009:adverse effects; D003365:Costs and Cost Analysis; D004311:Double-Blind Method; D012968:Etidronic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010001:Osteitis Deformans / Q000188:drug therapy*; D010024:Osteoporosis / Q000139:chemically induced / Q000188:drug therapy*; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy; D010919:Placebos; D016032:Randomized Controlled Trials as Topic; D000068296:Risedronic Acid; D013997:Time Factors
D002121:Calcium Channel Blockers; D010919:Placebos; D000068296:Risedronic Acid; D012968:Etidronic Acid; D003348:Cortisone